AN2 Therapeutics - רווח למניה אחת ב-12 החודשים האחרונים ANTX

The development of therapies for rare pulmonary pathologies possesses absolute resilience to crises and seasonality for AN2 Therapeutics, Inc. (ANTX). The rolling annual net income per share growth rate visualizes the market consensus, while 16.80 records a new level. Future revenues depend on the outcome of clinical trials, while diversified raw material supply chains eliminate the risk of logistical disruptions.
AN2 Therapeutics Inc - פילוחים אנליטיים ומדדי מפתח (ANTX)

This indicator captures the annual trend of net earnings per share over a rolling twelve-month period, allowing investors to assess the actual scaling pace of business profitability. Investments by AN2 Therapeutics, Inc. (ANTX) in sustainable disposal and cold chain optimization directly impact operating expenses, which is reflected in the EPS YoY TTM shift and confirms the company's financial stability.